J Clin Neurol.  2015 Oct;11(4):305-310. 10.3988/jcn.2015.11.4.305.

Postthrombolytic Antiplatelet Use for Patients with Intercerebral Hemorrhage without Extensive Parenchymal Involvement Does Not Worsen Outcome

Affiliations
  • 1Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China. yongjunwang1962@gmail.com
  • 2Department of Neurology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Abstract

BACKGROUND AND PURPOSE
It is unclear whether postthrombolytic antiplatelet (AP) therapy after thrombolytic-related hemorrhage without extensive parenchymal involvement (THEPI) affects the clinical outcome. This study explored whether AP administration in patients with THEPI affects short- and long-term outcomes.
METHODS
All of the data for this study were collected from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) registry. Patients with THEPI were assigned to either the AP (AP therapy should be commenced 24 h after intravenous thrombolysis) or AP-naive groups. THEPI was defined according to European-Australasian Acute Stroke Study II criteria. The 90-day functional outcome, 7-day National Institutes of Health Stroke Scale (NIHSS) score, and 7-day and 90-day mortalities were compared between the AP and AP-naive groups. Logistic regression analysis was used to evaluate the effects of AP therapy on the short- and long-term clinical outcomes.
RESULTS
Of the 928 patients enrolled from those in the TIMS-China registry (n=1,440), 89 (9.6%) had nonsymptomatic intracerebral hemorrhage (ICH) within 24-36 h after thrombolysis; 33 (37%) of these patients were given AP therapy (AP group) and 56 (63%) were not (AP-naive group). No significant differences were found for the risk of 7-day aggravated ICH (p=0.998), 7-day NIHSS score (p=0.5491), 7-day mortality [odds ratio (OR)=3.427; 95% confidence interval (95% CI)=0.344-34.160; p=0.294], 90-day mortality (OR=0.788, 95% CI=0.154-4.040, p=0.775), or modified Rankin score 5 or 6 at 90-days (OR=1.108, 95% CI=0.249-4.928, p=0.893) between the AP and AP-naive groups after THEPI.
CONCLUSIONS
Early administration of postthrombolytic AP therapy after THEPI does not worsen either the short- or long-term outcome. AP therapy may be a reasonable treatment option for patients with THEPI to reduce the risk of ischemic stroke recurrence.

Keyword

ischemic stroke; thrombolytic-related hemorrhage; antiplatelet therapy; outcome

MeSH Terms

Cerebral Hemorrhage
China
Hemorrhage*
Humans
Logistic Models
Mortality
National Institutes of Health (U.S.)
Recurrence
Stroke

Figure

  • Fig. 1 Numbers of eligible study patients in the TIMS-China registry. AP: antiplatelet, ICH: intracerebral hemorrhage, NIHSS: National Institutes of Health Stroke Scale, rt-PA: recombinant tissue plasminogen activator, sICH: symptomatic ICH, TIMS-China: Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China.

  • Fig. 2 Comparison of function in different types of THEPI in the AP group at the 7- and 90-day follow-ups in patients from TIMS-China. AP: antiplatelet, ICH: intracerebral hemorrhage, mRS: modified Rankin Scale, THEPI: thrombolytic-related hemorrhage without extensive parenchymal involvement, TIMS-China: Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China.

  • Fig. 3 Comparison of function in different types of THEPI in the AP-naïve group at the 7- and 90-day follow-ups in patients from TIMS-China. AP: antiplatelet, ICH: intracerebral hemorrhage, mRS: modified Rankin Scale, THEPI: thrombolytic-related hemorrhage without extensive parenchymal involvement, TIMS-China: Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China.


Reference

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333:1581–1587.
2. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352:1245–1251.
Article
3. Sussman ES, Connolly ES Jr. Hemorrhagic transformation: a review of the rate of hemorrhage in the major clinical trials of acute ischemic stroke. Front Neurol. 2013; 4:69.
Article
4. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke. 2006; 37:556–561.
Article
5. Molina CA, Alvarez-Sabín J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke. 2002; 33:1551–1556.
6. Kerenyi L, Kardos L, Szász J, Szatmári S, Bereczki D, Hegedüs K, et al. Factors influencing hemorrhagic transformation in ischemic stroke: a clinicopathological comparison. Eur J Neurol. 2006; 13:1251–1255.
Article
7. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45:2160–2236.
Article
8. Park JH, Ko Y, Kim WJ, Jang MS, Yang MH, Han MK, et al. Is asymptomatic hemorrhagic transformation really innocuous? Neurology. 2012; 78:421–426.
Article
9. Kent DM, Hinchey J, Price LL, Levine SR, Selker HP. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous? Stroke. 2004; 35:1141–1146.
Article
10. Libman R, Kwiakowski T, Lyden P, Grotta JC, Tilley BC, Fagen SC, et al. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. J Stroke Cerebrovasc Dis. 2005; 14:50–54.
Article
11. Kim JT, Heo SH, Park MS, Chang J, Choi KH, Cho KH. Use of antithrombotics after hemorrhagic transformation in acute ischemic stroke. PLoS One. 2014; 9:e89798.
Article
12. Liao XL, Wang CX, Wang YL, Wang CJ, Zhao XQ, Zhang LQ, et al. Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients. CNS Neurosci Ther. 2013; 19:43–47.
Article
13. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007; 369:275–282.
Article
14. Kimura K, Iguchi Y, Shibazaki K, Aoki J, Terasawa Y. Hemorrhagic transformation of ischemic brain tissue after t-PA thrombolysis as detected by MRI may be asymptomatic, but impair neurological recovery. J Neurol Sci. 2008; 272:136–142.
Article
15. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry. 2008; 79:1093–1099.
Article
16. Jickling GC, Liu D, Stamova B, Ander BP, Zhan X, Lu A, et al. Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab. 2014; 34:185–199.
Article
17. Jia W, Zhou L. Use of antiplatelets. A survey of secondary prevention of ischemic stroke with intracranial hemorrhage history in Chinese patients. Neurosciences (Riyadh). 2011; 16:335–339.
18. Kablau M, Kreisel SH, Sauer T, Binder J, Szabo K, Hennerici MG, et al. Predictors and early outcome of hemorrhagic transformation after acute ischemic stroke. Cerebrovasc Dis. 2011; 32:334–341.
Article
19. Dzialowski I, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD, et al. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke. 2007; 38:75–79.
Article
20. Wang Y, Liao X, Zhao X, Wang DZ, Wang C, Nguyen-Huynh MN, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke. 2011; 42:1658–1664.
Article
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr